Pomalidomide

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1319 publications

Rational design, molecular characterization and dissociation mechanisms of PROTACs targeting hFAAH.

Rational design, molecular characterization and dissociation mechanisms of PROTACs targeting hFAAH.

Journal: Physical chemistry chemical physics : PCCP

Published: June 23, 2026

Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care.

Clinical characteristics and risk factors for pomalidomide-induced skin rash: Implications for pharmacist-led monitoring in real-world multiple myeloma care.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: June 17, 2026

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Talquetamab-Daratumumab in Relapsed or Refractory Myeloma.

Journal: The New England journal of medicine

Published: June 15, 2026

Recent advances in management of systemic AL amyloidosis

Recent advances in management of systemic AL amyloidosis

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: June 03, 2026

A Single Center Real-World Study of the Efficacy of Daratumumab-Based Regimens in the Treatment of Relapsed/Refractory Multiple Myeloma Patients

A Single Center Real-World Study of the Efficacy of Daratumumab-Based Regimens in the Treatment of Relapsed/Refractory Multiple Myeloma Patients

Journal: Zhongguo shi yan xue ye xue za zhi

Published: June 02, 2026

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy.

Journal: The New England journal of medicine

Published: May 29, 2026

Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer.

Ultrahigh-Throughput Liquid Chromatography with Tandem Mass Spectrometry Method for Targeted Protein Degradation Compound Screening Using the Orbitrap Astral Mass Spectrometer.

Journal: Journal of proteome research

Published: May 06, 2026

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Patterns of care in relapsed/refractory multiple myeloma in China: a real-world physician survey study.

Journal: Future oncology (London, England)

Published: April 13, 2026

A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-Monothiopomalidomide.

A new therapeutic approach for Parkinson's disease: dual targeting of α-Synuclein aggregation and microglial function by the novel immunomodulator 3-Monothiopomalidomide.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Inflation Reduction Act impact on the hematology/oncology treatment landscape.

Inflation Reduction Act impact on the hematology/oncology treatment landscape.

Journal: The American journal of managed care

Published: March 26, 2026

Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients.

Pomalidomide significantly enhances the antitumor immune efficacy of dendritic cell-derived exosomes from multiple myeloma patients.

Journal: Journal of translational medicine

Published: March 22, 2026

Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines.

Synthesis and Evaluation of a Potential RSK2 Degrader in Human Multiple Myeloma Cell Lines.

Journal: Chemical & pharmaceutical bulletin

Published: March 18, 2026

Showing 1-12 of 1,319

Last Updated: 06/30/2026